A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor

Study Identifier
M23-492
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Healthy Volunteer
  • Study Drug
  • Galicaftor
  • Navocaftor
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 65 Years

    Protocol Summary

    Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The objectives of this study are to assess the effect of food on the safety and pharmacokinetics of navocaftor and galicaftor.

    Study Locations

    Location
    Status
    Location
    Clinical Pharmacology of Miami /ID# 249531
    Miami, Florida, United States, 33014
    Status
    Not applicable
    Location
    Acpru /Id# 249532
    Grayslake, Illinois, United States, 60030
    Status
    Not applicable